TEMPI syndrome: A clinical, light-microscopic and phenotypic evaluation with review of the literature.

J Cutan Pathol

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.

Published: April 2024

Background And Objectives: TEMPI (telangiectasias, elevated erythropoietin and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonaryshunting) syndrome is a rare multisystemic disease classified as a monoclonal gammopathy of cutaneous significance. The pathogenesis and etiology of TEMPIare not well known because of the rarity of this disorder. Although telangiectasias are the hallmark of this syndrome, skin biopsies are rarely performed. We aim to further characterize TEMPI syndrome through the evaluationof a skin biopsy.

Methods: We reviewed the histopathology and immunophenotypic profile of a skin biopsy from a 53-year-oldwoman diagnosed with TEMPI syndrome. Other components of her syndromic complex included an IgA myeloma, elevated vascular endothelial growth factor (VEGF), and erythrocytosis.

Results: A biopsy showed prominent vascular ectasia with some degree of microvascular basement membranezone thickening. Our patient had a reduction in neoplastic plasma cell burdenand clearing of her telangiectasias following myeloma directed treatment.

Conclusions: TEMPI can beviewed as a reactive vascular paraneoplastic syndrome in the setting of a plasma cell dyscrasia. Elaboration of VEGF from neoplastic plasma cells is likely pathogenetically implicated and appears to be a common link that explains other vascular lesions associated with monoclonal gammopathy syndromes.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.14572DOI Listing

Publication Analysis

Top Keywords

tempi syndrome
12
monoclonal gammopathy
12
neoplastic plasma
8
plasma cell
8
tempi
5
syndrome
5
syndrome clinical
4
clinical light-microscopic
4
light-microscopic phenotypic
4
phenotypic evaluation
4

Similar Publications

Article Synopsis
  • TEMPI syndrome combines features like telangiectasias, polycythemia with high erythropoietin levels, monoclonal gammopathy, and has a link to plasma cell neoplasms, but its exact cause is still unclear.
  • The use of F-FDG PET imaging is valuable for initial evaluation and treatment monitoring in conditions like multiple myeloma and has been applied successfully for a TEMPI patient, showing significant treatment responses.
  • In a 51-year-old woman, post-treatment F-FDG PET scans indicated complete reduction of bone lesions and normalization of symptoms, suggesting the effectiveness of the treatment and the potential of F-FDG PET in managing TEMPI syndrome.
View Article and Find Full Text PDF

TEMPI syndrome: difficult to diagnose, "easy" to treat?

Ann Hematol

September 2024

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Vas Sofias 80, Athens, 11528, Greece.

Article Synopsis
  • TEMPI syndrome is a rare plasma cell disorder that affects multiple systems and is characterized by symptoms like telangiectasias, erythrocytosis, and monoclonal gammopathy.
  • A specific case study details a 73-year-old man diagnosed with TEMPI syndrome after experiencing severe renal issues and erythrocytosis, who responded positively to treatment with Dara-VCD.
  • Preliminary research indicates lower levels of certain cytokines in TEMPI patients, suggesting a possible link between cytokine deregulation and ischemic changes in the kidneys, although further investigation is needed to establish a direct connection.
View Article and Find Full Text PDF

: the first rearrangement gene identified in TEMPI syndrome.

Haematologica

August 2024

Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; Department of General Practice, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on a bispecific antibody, JNJ-67571244, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), aiming to identify maximum tolerated dose and safety outcomes.
  • The phase I trial, involving 68 patients, encountered significant side effects and toxicity, with 88.2% showing treatment-emergent adverse events, while no substantial clinical responses were observed.
  • The prolonged treatment strategy intended to enhance tolerability did not prevent adverse effects, and the study was terminated without achieving the planned exposure levels for determining effective dosing.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!